AMELIVU

Welcome to the Brand page for “AMELIVU”, which is offered here for Pharmaceutical preparations for treating neovascular age-related macular degeneration; pharmaceutical preparations for treating diabetic macular edema; pharmaceutical preparations for the treatment of angiogenesis diseases and disorders; eye drops; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for ocular or intraocular surgery; ocular pharmaceuticals; ophthalmic preparations; pharmaceutical preparations for treating diabetes; human vaccine preparations; preparations for medical use, preparations, biological formulations, biological preparations, antibody formulations and protein formulations, for immunoregulation and for the treatment of immunologic disorders, autoimmune diseases, inflammatory diseases, arthritis, cancer, tumor, central nervous system disorders and metabolic diseases; pharmaceutical preparations for the treatment of inflammatory diseases; antidiabetic preparations; pharmaceutical preparations for the treatment of metabolic diseases and disorders; pharmaceutical preparations for the prevention of ocular disorders or diseases; cardiovascular agents for medical purposes; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; dietary supplements;.

Its status is currently believed to be active. Its class is unavailable. “AMELIVU” is believed to be currently owned by “SAMSUNG BIOEPIS CO., LTD.”